Sign in

AMRS on NASDAQ

Amyris

Logo: Amyris, Public domain, via Wikimedia Commons4

Sustainable synthetic ingredients for consumer products based in Emeryville, founded in 20031

In its 2023 annual report the company says: “Amyris is a biotechnology company delivering sustainable, science-based ingredients and consumer products that are better than incumbent options for people and the planet. Our proprietary sustainable ingredients are sold in bulk to industrial leaders who serve Flavor & Fragrance (F&F), Nutrition, Food & Beverage, and Clean Beauty & Personal Care end markets.”106 Its shares trade on NASDAQ under the symbol AMRS.1

Price unavailable

Last updated Oct 21, 2026.

Overview

2003Founded1

Compare with AEMETIS, INC, Gevo, Inc or REX American Resources, or pick any stock.

  • TickerAMRS on NASDAQ1
  • IndustryIndustrial Organic Chemicals1
  • HeadquartersEmeryville1
  • Websitewww.amyris.com
  • Legal formDelaware corporation1
  • Incorporated inDE5
  • Business address5885 Hollis Street, Suite 100, Emeryville, Ca 946085
  • Filer categoryAccelerated filer5
  • LEI549300BG17WCUK6EIM583
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States3
  • Registered withDivision of Corporations, Department of State, 47686333

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-210.9%Operating margin6
-195.9%Net margin6
-21.1%Revenue growth, 20226

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue29¢$258.7M
  • Research and development12¢$110.2M
  • Selling, general and admin55¢$493.6M
  • Interest3¢$24.7M
  • Income tax0¢$2.7M

Out of $269.8M in revenue.6 The company lost money this year.

Financial statements

Revenue789106$269.8M in 2022+302% since 2016
0$100.0M$200.0M$300.0M$400.0M2016: $67.2M$67.2M20162017: $127.7M$127.7M2017+90%2018: $63.6M$63.6M2018−50%2019: $152.6M$152.6M2019+140%2020: $173.1M$173.1M2020+13%2021: $341.8M$341.8M2021+97%2022: $269.8M$269.8M2022−21%
Operating income789106-$569.0M in 2022+493% since 2016
-$600.0M-$400.0M-$200.0M02016: -$95.9M-$95.9M20162017: -$56.1M-$56.1M2017−42%2018: -$136.6M-$136.6M2018+144%2019: -$121.9M-$121.9M2019−11%2020: -$123.4M-$123.4M2020+1%2021: -$177.6M-$177.6M2021+44%2022: -$569.0M-$569.0M2022+220%
Net income789106-$528.5M in 2022+443% since 2016
-$600.0M-$400.0M-$200.0M02016: -$97.3M-$97.3M20162017: -$156.0M-$156.0M2017+60%2018: -$230.2M-$230.2M2018+48%2019: -$242.8M-$242.8M2019+5%2020: -$331.0M-$331.0M2020+36%2021: -$271.0M-$271.0M2021−18%2022: -$528.5M-$528.5M2022+95%
Fiscal year2016201720182019202020212022
Revenue$67.2M7$127.7M8$63.6M9$152.6M10$173.1M6$341.8M6$269.8M6
Cost of revenue$56.7M7$62.3M8$36.7M9$76.2M10$87.8M6$155.1M6$258.7M6
Research and development$51.4M7$57.6M8$68.7M9$71.5M10$71.7M6$94.3M6$110.2M6
Selling, general and admin$47.7M7$63.9M8$90.9M9$126.6M10$137.1M6$257.8M6$493.6M6
Operating expenses$519.4M6$838.8M6
Operating income-$95.9M7-$56.1M8-$136.6M9-$121.9M10-$123.4M6-$177.6M6-$569.0M6
Interest$37.6M7$37.1M8$42.7M9$58.7M10$48.0M6$25.6M6$24.7M6
Income before tax-$272.3M6-$538.6M6
Income tax$553.0K7$6.9M8$09$629.0K10$293.0K6-$8.1M6-$2.7M6
Net income-$97.3M7-$156.0M8-$230.2M9-$242.8M10-$331.0M6-$271.0M6-$528.5M6
Earnings per share-$6.127-$2.897-$3.699-$2.6710-$1.886-$0.936-$1.656
Earnings per share (diluted)-$6.557-$2.897-$3.699-$2.7210-$1.886-$0.976-$1.696
Shares (weighted, basic)292.3M shares6320.8M shares6
Shares (weighted, diluted)292.7M shares6339.3M shares6

Compare Amyris with another company

Corporate structure

Amyris sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Amyris

  • Amyris Emeryville, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Amyris reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$285.6M6 Dec 31, 2022$158.5M6 Dec 31, 2021+80.1%
Accumulated depreciation$103.4M6 Dec 31, 2022$85.7M6 Dec 31, 2021+20.6%
Property and equipment, net$182.2M6 Dec 31, 2022$72.8M6 Dec 31, 2021+150.2%
Finance-lease assets$152.0K6 Dec 31, 2022$7.3M6 Dec 31, 2021−97.9%
Operating-lease assets (leased space)$97.2M6 Dec 31, 2022$32.4M6 Dec 31, 2021+199.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$64.4M6 Dec 31, 2022$483.5M6 Dec 31, 2021−86.7%
Stakes in other companies (equity method)$3.0M6 Dec 31, 2022$9.4M6 Dec 31, 2021−68.2%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$142.6M6 Dec 31, 2022$131.3M6 Dec 31, 2021+8.6%
Intangible assets, net (excluding goodwill)$46.9M6 Dec 31, 2022$39.3M6 Dec 31, 2021+19.5%
Finite-lived intangibles, gross$51.3M6 Dec 31, 2022$40.2M6 Dec 31, 2021+27.5%
Accumulated amortization$4.4M6 Dec 31, 2022$978.0K6 Dec 31, 2021+345.6%
Finite-lived intangibles, net$46.9M6 Dec 31, 2022$39.3M6 Dec 31, 2021+19.5%

Inventory

ItemLatestA year beforeChange
Inventory, total$111.9M6 Dec 31, 2022$75.1M6 Dec 31, 2021+49.0%
Raw materials$43.0M6 Dec 31, 2022$25.7M6 Dec 31, 2021+67.3%
Work in process$8.0M6 Dec 31, 2022$6.9M6 Dec 31, 2021+15.7%
Finished goods$60.8M6 Dec 31, 2022$42.4M6 Dec 31, 2021+43.4%

Leadership

Who has led Amyris, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. John Melo2010–2022
  2. Paulo Sergio De Oliveira Diniz2011–2013
  3. Hermanus Kieftenbeld2024

President

  1. John Melo2010–2022
  2. Joel Cherry2011–2019
  3. Mario Portela2012

Chief financial officer

  1. Jeryl L. Hilleman2010–2011
  2. Steven Richard Mills2012–2013
  3. Paulo Sergio De Oliveira Diniz2013–2014
  4. Raffi Asadorian2015–2017
  5. Kathleen Valiasek2017–2019
  6. Jonathan Wolter2019
  7. Hermanus Kieftenbeld2020–2024

Chief operating officer

  1. Mario Portela2010–2011
  2. Eduardo Alvarez2017–2023
20052010201520202025
Board members and other officers (52)

Former names

  • AMYRIS BIOTECHNOLOGIES INCMay 30, 2006 to May 25, 20105

Timeline

  1. May 7, 2024New chief executive Hermanus Kieftenbeld becomes CEO15
  2. May 7, 20248-K Entered a material agreement; Ended a material agreement; New debt or obligation77
  3. Apr 23, 20248-K Regulation FD disclosure78
  4. Apr 8, 20248-K Regulation FD disclosure79
  5. Feb 28, 20248-K Regulation FD disclosure80
  6. Feb 9, 20248-K Bankruptcy or receivership; Exit or restructuring costs; Change to shareholders' rights81
  7. Jan 4, 20248-K Entered a material agreement82
  8. Dec 29, 20238-K Entered a material agreement; Completed an acquisition or sale; Exit or restructuring costs83
  9. Dec 27, 20238-K Executive or director change84
  10. Dec 13, 20238-K Entered a material agreement; Regulation FD disclosure85
  11. Nov 29, 20238-K Regulation FD disclosure86
  12. Nov 22, 20238-K Regulation FD disclosure87
  13. Nov 7, 20238-K Regulation FD disclosure88
  14. Mar 4, 2011New chief executive Paulo Sergio De Oliveira Diniz becomes CEO16
  15. Sep 28, 2010Went public Listed on NASDAQ1
  16. Sep 27, 2010New chief executive John Melo becomes CEO17
  17. 2003Founded Founded1

Calendar

When it reported results

  1. May 9, 2023Reported quarterly or annual results89
  2. Apr 24, 2023Reported quarterly or annual results90
  3. Mar 15, 2023Reported quarterly or annual results91
  4. Nov 8, 2022Reported quarterly or annual results92
  5. Aug 9, 2022Reported quarterly or annual results93
  6. May 10, 2022Reported quarterly or annual results94
  7. Mar 1, 2022Reported quarterly or annual results95
  8. Jan 13, 2022Reported quarterly or annual results96

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

237 filings to the SEC since October 2021: 2 annual reports, 5 quarterly reports, 55 major events, 67 insider forms, 29 large holders, 1 private raises, 78 other. The latest 20:

  1. May 7, 20244 EDGAR
  2. May 7, 20244 EDGAR
  3. May 7, 20244 EDGAR
  4. May 7, 20244 EDGAR
  5. May 7, 20244 EDGAR
  6. May 7, 20244 EDGAR
  7. May 7, 20244 EDGAR
  8. May 7, 20244 EDGAR
  9. May 7, 20244 EDGAR
  10. May 7, 2024SC 13D/A EDGAR
  11. May 7, 202415-12G EDGAR
  12. May 7, 20248-K EDGAR
  13. May 7, 20244 EDGAR
  14. Apr 23, 20248-K EDGAR
  15. Apr 8, 20248-K EDGAR
  16. Apr 2, 2024NT 10-K EDGAR
  17. Feb 28, 20248-K EDGAR
  18. Feb 21, 2024EFFECT EDGAR
  19. Feb 21, 2024EFFECT EDGAR
  20. Feb 21, 2024EFFECT EDGAR

The 237 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

19 open-market trades by officers, directors and large owners since October 2021: 2 buys and 17 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 2, 2023Kieftenbeld HermanusCFO AND INTERIM CEOSale20,999$0.95$19.9KForm 4
Apr 5, 2023ALVAREZ EDUARDOCHIEF OPERATING OFFICERSale231,368$1.23$284.6KForm 4
Sep 21, 2022Kung FrankDirectorSale200,000$3.50$700.0KForm 4
Sep 21, 2022Kung FrankDirectorSale200,000$3.50$700.0KForm 4
Sep 20, 2022Kung FrankDirectorSale400,000$3.60$1.4MForm 4
Sep 20, 2022Kung FrankDirectorSale400,000$3.60$1.4MForm 4
Sep 19, 2022Kung FrankDirectorSale1,080,676$3.80$4.1MForm 4
Sep 16, 2022Kung FrankDirectorSale833,100$3.60$3.0MForm 4
Sep 15, 2022Kung FrankDirectorSale1,385,000$4.20$5.8MForm 4
Sep 2, 2022KELSEY NICOLECHIEF LEGAL OFFICER- SECRETARYSale5,019$2.87$14.4KForm 4
Sep 2, 2022ALVAREZ EDUARDOCHIEF OPERATING OFFICERSale22,421$2.87$64.3KForm 4
Sep 2, 2022Kieftenbeld HermanusCFO AND INTERIM CEOSale25,888$2.87$74.3KForm 4
Aug 15, 2022Melo JohnPresident and CEOBuy17,155$4.03$69.1KForm 4
Jul 6, 2022Melo JohnPresident and CEOSale55,576$2.12$117.9KForm 4
Jun 30, 2022KELSEY NICOLECHIEF LEGAL OFFICER- SECRETARYSale94,033$1.80$169.3KForm 4
Jun 2, 2022Hughes AnthonyCHIEF ACCOUNTING OFFICERSale6,305$2.34$14.8KForm 4
Jun 2, 2022KELSEY NICOLECHIEF LEGAL OFFICER- SECRETARYSale8,406$2.34$19.7KForm 4
Jun 2, 2022Kieftenbeld HermanusCFO AND INTERIM CEOSale34,905$2.34$81.7KForm 4
Dec 6, 2021MCCANN JAMES FDirectorBuy17,400$5.71$99.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$8.0M 2022–2022
Money received by yearMoney received by year, 2022–2022: $8.0M in all. Private raises (Form D) $8.0M.$0$2M$4M$6M$8M2022 · Private raises (Form D): $8.0M2022
Figures by year
YearPrivate raises (Form D)Total
2022$8.0M$8.0M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Sep 13, 2022Raised $8 million in a private offering of equity105 Form D: 1 investor so far Form D

SEC filer profile

How Amyris is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAMYRIS, INC.2
  • CIK0001365916
  • Employer ID (EIN)55-08561512
  • Filer statusAccelerated filer2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2860 Industrial Organic Chemicals2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address5885 Hollis Street, Suite 100, Emeryville, CA 946082
  • Phone510-450-07612
  • Shares outstanding369,385,614 as of May 5, 202313
  • Public float$340.4M as of Jun 30, 20226
  • On EDGAR sinceMay 30, 20062
  • Filings1,530 in all: 4 (541), 8-K (344), 3 (65), SC 13D/A (53), D (49), SC 13G/A (41), 10-Q (38), 4/A (31)2
    All 50 form types

    EFFECT (31), CT ORDER (29), CORRESP (22), SC 13G (22), DEF 14A (18), UPLOAD (18), POS AM (17), PRE 14A (16), 424B7 (15), S-8 (15), S-8 POS (15), 10-K (13), DEFA14A (13), S-3 (12), REGDEX/A (10), NT 10-K (9), S-1/A (9), 424B5 (8), 424B3 (7), 8-K/A (7), NT 10-Q (7), S-3/A (6), 10-K/A (5), ARS (5), D/A (5), 5 (4), S-1 (4), SC 13D (4), IRANNOTICE (3), REGDEX (3), SEC STAFF LETTER (3), 144 (2), 3/A (2), 144/A (1), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERTNAS (1), POSASR (1), PRER14A (1), S-3ASR (1)

  • Latest filingsAnnual report (10-K) Mar 16, 2023
    Quarterly report (10-Q) May 10, 2023
    Proxy statement (DEF 14A) Apr 11, 2023
    Latest 8-K (8-K) May 7, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95
  96. 96
  97. 97
  98. 98
  99. 99
  100. 100
  101. 101
  102. 102
  103. 103
  104. 104
  105. 105
  106. 106